Pharmacogenomic Data “Regulatory Impact” To Be Outlined In Guidance
Executive Summary
The regulatory impact of different categories of pharmacogenomic data will be addressed in a draft guidance, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Science Board Advisory Committee meeting April 9
You may also be interested in...
Pharmacogenomics draft guidance
FDA is understood to be on track to release its pharmacogenomics draft guidance in August. The draft guidance is understood to state that FDA will not require sponsors to collect pharmacogenomics data for product applications (1"The Pink Sheet" April 14, 2003, p. 12). The Drug Information Association is planning a meeting on pharmacogenomics for November...
Pharmacogenomics draft guidance
FDA is understood to be on track to release its pharmacogenomics draft guidance in August. The draft guidance is understood to state that FDA will not require sponsors to collect pharmacogenomics data for product applications (1"The Pink Sheet" April 14, 2003, p. 12). The Drug Information Association is planning a meeting on pharmacogenomics for November...
FDA Pharmacogenomic Regulation: Three Guidances, Fall Workshop
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months